



Re: pioglitazone web statement [SEC=UNCLASSIFIED] 

Nick Simpson to: 


Cc: Jane Cook

14/07/2011 03:04 PM

Dear 

Thank you for the suggestions, which we will consider before finalising the text.

Nick

 Dear Nick Thank you for the opportunity to re...

14/07/2011 02:50:57 PM

From: 

To: Nick.Simpson 

Date: 14/07/2011 02:50 PM


Subject: Re: pioglitazone web statement [SEC=UNCLASSIFIED]




Dear Nick

Thank you for the opportunity to review the statement, we had a couple of suggestions which are shown in the attachment via track changes. The suggestions are primarily to align with the terminology in our dear doctor letter, please let me know if you would like to discuss any of our suggestions.


(See attached file: TGA advisory - pioglitazone and bladder cancer - final draft (NS 13.07.11)_EL Comments.docx)

Kind Regards


(Embedded image moved to file: pic04472.jpg)


Medical Division
Eli Lilly Australia Pty Limited
112 Wharf Road West Ryde NSW 2114 AUSTRALIA
Ph: 
Fax: 
W : www.lilly.com.au
Sig_Lg_fullc_Red
image moved to file: pic18434.gif)lilly logo

(Embedded image moved to file: pic07128.jpg)
(Embedded

In the interests of PATIENT SAFETY if your email relates to an adverse event or a clinical trial adverse event, please contact the Product Safety department as soon as possible at AU_Drug_Safety  or phone +61 (0) 2 9325 4676.

CONFIDENTIALITY NOTICE: This e-mail message from Eli Lilly Australia Pty Limited (including all attachments) is for the sole use of the

intended recipient(s) and may include confidential information. Any unauthorised review, use, disclosure, alteration or distribution is strictly prohibited.
If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

Nick.Simpson [REDACTED]

13/07/2011 01:13
PM

To
[REDACTED]
Cc

Subject
pioglitazone web statement
[SEC=UNCLASSIFIED]

Dear [REDACTED]

Attached is a draft web statement regarding pioglitazone and bladder cancer risk.

Please let me know as soon as possible if you see any factual errors or have any other concerns.

kind regards

Nick

.....
Nick Simpson MBBS MPH PhD

Medical Officer | Signal Investigation | Office of Product Review |
Monitoring and Compliance Group
Therapeutic Goods Administration | Commonwealth Department of Health and Ageing

phone 02 6232 8092 | fax 02 6232 8392 | nick.simpson [REDACTED] |
<http://www.tga.gov.au>

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information and has been sent in accordance with the TGA security policy.

If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author Immediately and delete all copies of this transmission."

[attachment "TGA advisory - pioglitazone and bladder cancer - final draft (NS 13.07.11).doc" deleted by ██████████]

[attachment "TGA advisory - pioglitazone and bladder cancer - final draft (NS 13.07.11) _EL Comments.docx" deleted by Nick Simpson/TGA/Health]

[attachment "pic04472.jpg" deleted by Nick Simpson/TGA/Health] [attachment "pic07128.jpg" deleted by Nick Simpson/TGA/Health] [attachment "pic18434.gif" deleted by Nick Simpson/TGA/Health]